Fujita, Toshitsugu http://orcid.org/0000-0002-9536-9999
Nagata, Shoko
Fujii, Hodaka http://orcid.org/0000-0003-1296-4256
Article History
Received: 22 December 2020
Accepted: 28 July 2021
First Online: 19 August 2021
Competing interests
: T.F. and H.F. have filed patent applications for ORNi-RPA, CRISPRi-RPA, and MBDi-RPA with details as follows: (1) Name: method for suppressing amplification of specific nucleic acid sequences; number: Japanese Patent Application Nos. 2014-176018 and 2015-165643; status: under review; specific aspect of manuscript covered in the patent application: the basic principle of ORNi-RPA described in this manuscript. (2) Name: method for detecting differences in the target nucleic acid region; number: Japanese Patent Application Nos. 2018-81752, 2019-555516, and PCT/JP2019/16843; status: registered; Japanese Patent No. 6653932; specific aspect of manuscript covered in the patent application: application of ORNi-RPA to detection of nucleotide differences.; (3) name: method for detecting target nucleic acid, a method for detecting molecule having the nucleic acid binding ability, and method for evaluating nucleic acid binding ability; number: Japanese Patent Application No. 2019-191409 and PCT/JP2020/39128; status: filed; specific aspect of manuscript covered in the patent application: application of CRISPRi-RPA and MBDi-RPA to detection of differences of nucleotides and epigenetic status. Epigeneron, Inc. owns the rights for the commercial use of ORNi-RPA, CRISPRi-RPA, and MBDi-RPA. T.F. and H.F. are co-founders of Epigeneron, Inc. and own stock in the company. H.F. is one of the directors of Epigeneron, Inc. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The remaining author declares no competing interests.